



Technology Offer

Ref.-No. M0717

ERGOSTEROL-BIOSYNTHESIS INHIBITOR AND INFLUENZA VIRUS INFECTION

Introduction

Viral infection is not only extremely harmful to human health, but also severely endangers the survival and breeding of various animals, and thus becoming an important research task in medical and relevant fields currently.

Acute viral infectious disease of the upper respiratory tract such as influenza (shortened as "flu") is one of the most common infectious diseases. It has some features, such as a strong infectivity, a rapid spreading ability, a short latent period, and a high morbidity. Influenza is a viral infectious disease commonly suffered in human, avian and livestock.

The investigation of pharmaceuticals for preventing and treating influenza virus has drawn a lot of attention, as currently only protection against known circulating strains of the influenza virus exists.


Thus, there is a need in the art for new therapy and prophylaxis treatment of influenza-virus infections.

Invention

The present invention relates to an ergosterol-biosynthesis inhibitor for use in a method of treatment or prophylaxis of an influenza virus infection in a subject. The ergosterol-biosynthesis inhibitor is a compound comprising at least one 1*H*-1,2,4-triazole-1-yl group and is selected from the group consisting of itraconazole, posaconazole, voriconazole, fluconazole or fosfluconazole.

Patent situation

A provisional patent application has been filed.



Measuring viral titers in cells infected with H1N1 influenza-A-virus after treatment with posaconazole or itraconazole.

Advantages of the invention

By repurposing of known medicaments such as the ergosterol-biosynthesis inhibitor of the present invention, costs for development and approval may significantly be reduced.

People being treated with ergosterol-biosynthesis inhibitor as a medicament against other diseases such as fungal diseases may already be protected from suffering from influenza, thereby further reducing the costs for vaccination.

New aspects of the invention

Surprisingly it was found, that by repurposing the use of an ergosterol-biosynthesis inhibitor of the present invention being applied for a long time in therapy for other diseases such as fungal diseases, the ergosterol-biosynthesis inhibitor of the present invention are now used in the method of treatment or prophylaxis of an influenza virus infection by administering said ergosterol-biosynthesis inhibitor to a subject.

For further information please contact:

Clinic Invent

Dr. Elke Benkhart
Albert-Schweitzer-Campus 1, D3
D-48149 Münster

Tel. +49-(0)251/ 83 52077
E-Mail benkhart@uni-muenster.de